| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/12/2004 | CN1496275A Transdermal electrotransport device and method for mfg. same |
| 05/12/2004 | CN1496271A Method of treating diseases in association with decrease in expression of AOP-1 gene or AOP-1 and remedies for diseases |
| 05/12/2004 | CN1496264A 4-fluoro-N-indan-2-Y1 benzamide and its use as pharmaceutical |
| 05/12/2004 | CN1496262A Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists |
| 05/12/2004 | CN1496255A Inhibition of NF-KB by triterpene compositions |
| 05/12/2004 | CN1495198A Analogs of glucagon-like peptide-1 |
| 05/12/2004 | CN1495194A Application of steroid saponin for preventing and curing senile dementia and new steroid saponin |
| 05/12/2004 | CN1495170A Substituted pyrazolyl benzsulfamide compound for curing inflammation |
| 05/12/2004 | CN1495169A Pyridine-3-carboxylic acid derivative |
| 05/12/2004 | CN1495165A Indane or indoline derivative |
| 05/12/2004 | CN1495160A I-substituted-1-aminomethyl-cycloalkane derivative (gabapentin analogs), its preparation and application for curing neuropathy |
| 05/12/2004 | CN1495157A Preparation method of cyanophthaofluoroaniline |
| 05/12/2004 | CN1494899A Slowly-released dosage form containing asperline |
| 05/12/2004 | CN1149212C Peperidine derivatives as reuptake inhibitors |
| 05/12/2004 | CN1149209C Triazole compounds with dopamine-D3-receptor affinity |
| 05/12/2004 | CN1149204C 1-heterocycle substd. diarylamines |
| 05/12/2004 | CN1149201C Novel spiro imidazoline compounds, their prepn. method and medicinal compsns. containing same |
| 05/12/2004 | CN1149196C Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/12/2004 | CN1149195C 5-HTIF agonists |
| 05/12/2004 | CN1149191C Azetidine derivatives, Preparation and medicines containing them |
| 05/12/2004 | CN1149080C Prilocaine and hydrofluorocarbon aerosol preparations |
| 05/12/2004 | CN1149072C New pharmaceutical composition with anaesthetic effect |
| 05/11/2004 | US6734306 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 05/11/2004 | US6734301 2,3,4,5-Tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds |
| 05/11/2004 | US6734284 Exhibits high affinity for the gfr alpha 3- ret receptor complex and unique subregions in its amino acid sequence |
| 05/11/2004 | US6734204 Permit selective modulation of or even have opposing effects on different serotonin receptor subtypes |
| 05/11/2004 | US6734196 Substituted pyridine or piperidine compounds |
| 05/11/2004 | US6734195 Stable donepezil hydrochloride amorphous tablet for the treatment of dementia or alzheimer's disease |
| 05/11/2004 | US6734186 Phosphodiesterase 2 inhibitor |
| 05/11/2004 | US6734183 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 05/11/2004 | US6734179 Sulfur compounds such as 4-fluoro-n-(4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl) -benzamide, used as preferential adenosine receptor ligands for the prophylaxis of neurodegenerative disorders |
| 05/11/2004 | US6734176 Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| 05/11/2004 | US6734175 Administering to an obese patient or one at risk of becoming obese a therapeutic compound that attenuates the binding of agouti-related protein to melanocortin receptors, free of binding of alpha-melanocyte stimulating hormone to receptor |
| 05/11/2004 | US6734166 Method of reducing aluminum levels in the central nervous system |
| 05/11/2004 | US6733994 Highly expressible genes |
| 05/11/2004 | US6733981 Antibodies to interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 05/11/2004 | US6733783 Controlled release hydrocodone formulations |
| 05/11/2004 | CA2279428C Compounds and methods for therapeutic intervention in preventing diabetic complications |
| 05/11/2004 | CA2104594C Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 05/06/2004 | WO2004038411A2 Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
| 05/06/2004 | WO2004038408A2 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14) |
| 05/06/2004 | WO2004038407A2 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| 05/06/2004 | WO2004038406A2 Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42) |
| 05/06/2004 | WO2004038405A2 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
| 05/06/2004 | WO2004037863A1 Antibody and utilization of the same |
| 05/06/2004 | WO2004037854A1 Prion protein-binding peptide sequences |
| 05/06/2004 | WO2004037822A1 7-phenyl pyrazolopyridine compounds |
| 05/06/2004 | WO2004037820A1 Oxindole substituted piperazine derivatives |
| 05/06/2004 | WO2004037819A1 Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity |
| 05/06/2004 | WO2004037810A1 Selected cgrp antagonists, method for production and use thereof as medicament |
| 05/06/2004 | WO2004037809A1 Triazole compounds for the treatment of dysmenorrhoea |
| 05/06/2004 | WO2004037805A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 05/06/2004 | WO2004037801A1 Piperazinyl and diazapanyl benzamides and benzthioamides |
| 05/06/2004 | WO2004037800A1 Aryloxyalkylamine derivates as h3 receptor ligands |
| 05/06/2004 | WO2004037791A1 Inhibitors of glycogen synthase kinase 3 |
| 05/06/2004 | WO2004037788A1 Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases |
| 05/06/2004 | WO2004037769A2 Cycloalkylamides and their therapeutic use as antiepileptic and anticonvulsant |
| 05/06/2004 | WO2004037290A1 Sustained release composition for oral administration of drugs |
| 05/06/2004 | WO2004037281A1 Methods for neuroprotection |
| 05/06/2004 | WO2004037257A1 Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| 05/06/2004 | WO2004037254A1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 05/06/2004 | WO2004037246A1 Nerve fiber regeneration accelerator |
| 05/06/2004 | WO2004037241A1 Fused cycloalkyl amides and acids and their therapeutic applications for the treatment of i.a. epilepsy |
| 05/06/2004 | WO2004037240A1 Spirocyclopropyl amides and acids and their therapeutic applications |
| 05/06/2004 | WO2004037234A2 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| 05/06/2004 | WO2004037184A2 Methods for the treatment of skin disorders |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004018451A8 Pyridazinone-derivatives as pde4 inhibitors |
| 05/06/2004 | WO2004018044A3 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 05/06/2004 | WO2004016614A3 Pyrrolopyrazines as kinase inhibitors |
| 05/06/2004 | WO2004014953A3 Anti-myelin associated glycoprotein (mag) antibodies |
| 05/06/2004 | WO2004013143A3 Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands |
| 05/06/2004 | WO2004010950A3 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 05/06/2004 | WO2004009585A3 Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors |
| 05/06/2004 | WO2004004750A3 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 05/06/2004 | WO2004001068A3 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 05/06/2004 | WO2004000042A3 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| 05/06/2004 | WO2003106428A8 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists |
| 05/06/2004 | WO2003105893A3 Probiotic therapies using lactobacillus reuteri |
| 05/06/2004 | WO2003105838A3 MODULATION OF ACTIVATION OF GLUCOCORTICOID RECEPTORS beta-BREAKDOWN PRODUCTS OF GLUCOCORTICOIDS |
| 05/06/2004 | WO2003105779A3 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 05/06/2004 | WO2003099318A3 Pancreas-specific proteins |
| 05/06/2004 | WO2003096964A3 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac |
| 05/06/2004 | WO2003092580A3 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 05/06/2004 | WO2003090695A3 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY |
| 05/06/2004 | WO2003084482A3 Antidepressants and their analogues as long-acting local anesthetics and analgesics |
| 05/06/2004 | WO2003082853A8 New compounds |
| 05/06/2004 | WO2003072801A3 Compositions and method for regulation of calcium-dependent signalling in brain |
| 05/06/2004 | WO2003046008A9 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| 05/06/2004 | WO2003045316A9 Polynucleotide therapy |
| 05/06/2004 | WO2003040096A3 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 05/06/2004 | WO2003022298A3 Use of a protein of the crmp family for treating diseases related to the immune system |
| 05/06/2004 | WO2003016351B1 N - cam related compounds modulating cell groth |
| 05/06/2004 | WO2003004467A3 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 05/06/2004 | WO2002102800A9 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 05/06/2004 | WO2002092788A9 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 05/06/2004 | WO2002089800A3 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 05/06/2004 | WO2002088078A3 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES |
| 05/06/2004 | WO2002057222A9 Thiol-based naaladase inhibitors |
| 05/06/2004 | WO2002038108A3 Methods of treating disorders related to apoe |